How do naturally occurring YMDD-motif mutants influence the clinical course of lamivudine-naïve patients with chronic hepatitis B virus infection?

Journal of Gastroenterology and Hepatology (Australia)

Volumn 21, Issue 12, 2006, Pages 1769-1771

  Tsubota, Akihito ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC ACID; HEPATITIS B(E) ANTIBODY; LAMIVUDINE; METHIONINE; TYROSINE;

DISEASE ACTIVITY; DISEASE COURSE; DRUG INHIBITION; DRUG MECHANISM; EDITORIAL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION; MUTANT; PRIORITY JOURNAL; PROTEIN MOTIF; VIRUS CARRIER; VIRUS INFECTION; VIRUS LOAD; WORLD HEALTH ORGANIZATION;

EID: 33750490807     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2006.04768.x     Document Type: Editorial

References (27)

1. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N. Engl. J. Med. 1995; 333: 1657-61.
2. Nevens F, Main J, Honkoop P et al. Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroenterology 1997; 113: 1258-63.
3. Lai CL, Chien RN, Leung NW et al. A one-year trial of lamivudine for chronic hepatitis B. N. Engl. J. Med. 1998; 339: 61-8.
4. Chien RN, Liaw YF, Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Hepatology 1999; 30: 770-4.
5. Suzuki Y, Kumada H, Ikeda K et al. Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection. J. Hepatol. 1999; 30: 743-8.
6. Dienstag JL, Schiff ER, Wright TL et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N. Engl. J. Med. 1999; 341: 1256-63.
7. Liaw YF, Leung NW, Chang TT et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000; 119: 172-80.
8. Leung NW, Lai CL, Chang TT et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001; 33: 1527-32.
9. Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′- thiacytidine and related analogues. Proc. Natl. Acad. Sci. USA 1991; 88: 8495-9.
10. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996; 24: 714-17.
11. Allen MI, Deslauriers M, Andrews CW et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 1998; 27: 1670-7.
12. Stuyver LJ, Locarnini SA, Lok A et al. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 2001; 33: 751-7.
13. Chang TT, Lai CL, Liaw YF. Incremental increases in HBeAg seroconversion and continued ALT normalization in Asian chronic HBV (CHB) patients treated with lamivudine for years. Antivir. Ther. 2000; 5 (Suppl. 1): 44A (Abstract).
14. Lau DT, Khokhar MF, Doo E et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000; 32: 828-34.
15. Kobayashi S, Ide T, Sata M. Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers. J. Hepatol. 2001; 34: 584-6.
16. Kirishima T, Okanoue T, Daimon Y et al. Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment. J. Hepatol. 2002; 37: 259-65.
17. Matsuda M, Suzuki F, Suzuki Y et al. Low rate of YMDD motif mutations in polymerase gene of hepatitis B virus in chronically infected patients not treated with lamivudine. J. Gastroenterol. 2004; 39: 34-40.
18. Matsuda M, Suzuki F, Suzuki Y et al. YMDD mutants in patients with chronic hepatitis B before treatment are not selected by lamivudine. J. Med. Virol. 2004; 74: 361-6.
19. Ohishi W, Shirakawa H, Kawakami Y et al. Identification of rare polymerase variants of hepatitis B virus using a two-stage PCR with peptide nucleic acid clamping. J. Med. Virol. 2004; 72: 558-65.
20. Heo J, Cho M, Kim HH et al. Detection of YMDD motif mutants by oligonucleotide chips in lamivudine-untreated patients with chronic hepatitis B virus infection. J. Korean Med. Sci. 2004; 19: 541-6.
21. Huang ZM, Huang QW, Qin YQ et al. YMDD mutations in patients with chronic hepatitis B untreated with antiviral medicines. World J. Gastroenterol. 2005; 11: 867-70.
22. Akarsu M, Sengonul A, Tankurt E et al. YMDD motif variants in inactive hepatitis B carriers detected by INNO-LiPA HBV DR assay. J. Gastroenterol. Hepatol. 2006; 12: 1783-8.
23. Lee CH, Kim SO, Byun KS et al. Predominance of hepatitis B virus YMDD mutants is prognostic of viral DNA breakthrough. Gastroenterology 2006; 130: 1144-52.
24. Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001; 34: 785-91.
25. Zollner B, Schafer P, Feucht HH, Schroter M, Petersen J, Laufs R. Correlation of hepatitis B virus load with loss of e antigen and emerging drug-resistant variants during lamivudine therapy. J. Med. Virol. 2001; 65: 659-63.
26. Lai CL, Dienstag J, Schiff E et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin. Infect. Dis. 2003; 36: 687-96.
27. Tsubota A, Arase Y, Suzuki F et al. Severe acute exacerbation of liver disease may reduce or delay emergence of YMDD motif mutants in long-term lamivudine therapy for hepatitis B e antigen-positive chronic hepatitis B. J. Med. Virol. 2004; 73: 7-12.